Next Article in Journal / Special Issue
The Psychological Challenges of Replacing Conventional Karyotyping with Genomic SNP Array Analysis in Prenatal Testing
Previous Article in Journal / Special Issue
Fetal Aneuploidy Detection by Cell-Free DNA Sequencing for Multiple Pregnancies and Quality Issues with Vanishing Twins
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2014, 3(3), 693-712; doi:10.3390/jcm3030693

Maternal Serum Screening Markers and Adverse Outcome: A New Perspective

PerkinElmer Labs/NTD, 80 Ruland Road, Suite 1, Melville, NY 11747, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 9 April 2014 / Revised: 10 May 2014 / Accepted: 16 May 2014 / Published: 3 July 2014
(This article belongs to the Special Issue Prenatal Genetic Screening and Diagnosis-Part 2)
View Full-Text   |   Download PDF [393 KB, uploaded 3 July 2014]   |  

Abstract

There have been a number of studies evaluating the association of aneuploidy serum markers with adverse pregnancy outcome. More recently, the development of potential treatments for these adverse outcomes as well as the introduction of cell-free fetal DNA (cffDNA) screening for aneuploidy necessitates a re-evaluation of the benefit of serum markers in the identification of adverse outcomes. Analysis of the literature indicates that the serum markers tend to perform better in identifying pregnancies at risk for the more severe but less frequent form of individual pregnancy complications rather than the more frequent but milder forms of the condition. As a result, studies which evaluate the association of biomarkers with a broad definition of a given condition may underestimate the ability of such markers to identify pregnancies that are destined to develop the more severe form of the condition. Consideration of general population screening using cffDNA solely must be weighed against the fact that traditional screening using serum markers enables detection of severe pregnancy complications, not detectable with cffDNA, of which many may be amenable to treatment options.
Keywords: aneuploidy screening; preeclampsia; IUGR; preterm birth; fetal loss; placenta accreta; open neural tube defects aneuploidy screening; preeclampsia; IUGR; preterm birth; fetal loss; placenta accreta; open neural tube defects
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Krantz, D.; Hallahan, T.; Janik, D.; Carmichael, J. Maternal Serum Screening Markers and Adverse Outcome: A New Perspective. J. Clin. Med. 2014, 3, 693-712.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top